Recruiting XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma NCT06571734 Conditions Bone Diseases, Bone Neoplasms, Bone Sarcoma, +22 more Locations Northwestern University — Chicago, Illinois, United States View Trial Details
